预约演示
更新于：2025-06-03
Ezetimibe/Rosuvastatin Calcium
依折麦布/瑞舒伐他汀钙
更新于：2025-06-03
概要
基本信息
药物类型 小分子化药 |
别名 依折麦布瑞舒伐他汀钙、瑞舒伐他汀依折麦布、HCP-1306 + [12] |
作用方式 抑制剂 |
作用机制 HMG-CoA reductase抑制剂(羟甲基戊二酰辅酶A合酶抑制剂)、NPC1L1抑制剂(尼曼-匹克C1型类似蛋白-1抑制剂)、胆固醇吸收抑制剂 |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H28CaFN3O6S |
InChIKeyAVDMILNVMOXCHF-DHMAKVBVSA-N |
CAS号147098-20-2 |
查看全部结构式(2)
关联
84
项与 依折麦布/瑞舒伐他汀钙 相关的临床试验CTR20250895
瑞舒伐他汀依折麦布片（I）在健康受试者中空腹/餐后状态下的开放、随机、交叉生物等效性试验
CTR20250329
瑞舒伐他汀依折麦布片（Ⅰ）在中国健康受试者中进行的单中心、随机、开放、两制剂、单剂量、四周期、完全重复交叉、空腹及餐后状态下的生物等效性研究。
CTR20250536
健康受试者空腹单次口服瑞舒伐他汀依折麦布片（I）的随机、开放、单剂量、两制剂、两序列、四周期、完全重复交叉设计的生物等效性试验
100 项与 依折麦布/瑞舒伐他汀钙 相关的临床结果
登录后查看更多信息
100 项与 依折麦布/瑞舒伐他汀钙 相关的转化医学
登录后查看更多信息
100 项与 依折麦布/瑞舒伐他汀钙 相关的专利（医药）
登录后查看更多信息
7
项与 依折麦布/瑞舒伐他汀钙 相关的文献（医药）2022-01-01Journal of cardiovascular pharmacology and therapeutics
A Phase 3 Randomized Controlled Trial to Evaluate Efficacy and Safety of New-Formulation Zenon (Rosuvastatin/Ezetimibe Fixed-Dose Combination) in Primary Hypercholesterolemia Inadequately Controlled by Statins
Article
作者: Berthou, Baptiste ; Vrablik, Michal ; Baccara-Dinet, Marie ; Loy, Megan ; Catapano, Alberico L. ; Karpov, Yuri
Objective::
In primary hypercholesterolemia many people treated with statins do not reach their plasma LDL-C goals and are at increased risk of cardiovascular disease (CVD). This study aimed to evaluate efficacy and safety of a new fixed-dose combination (FDC) formulation of rosuvastatin/ezetimibe (R/E) in this population.
Methods::
This was a multicenter, multinational, randomized, double-blind, double-dummy, active-controlled, parallel-arm study of FDC R/E in people with primary hypercholesterolemia at very high risk (VHR) or high risk (HR) of CVD, inadequately controlled with 20 mg or 10 mg stable daily dose of rosuvastatin or equipotent dose of another statin. The primary objective was to demonstrate superiority of FDC R/E versus rosuvastatin monotherapy uptitrated to 40 mg (R40) or 20 mg (R20) in reduction of LDL-C after 6 weeks.
Results::
Randomized VHR participants (n = 244) were treated with R40, R40/E10, or R20/E10; randomized HR participants (n = 208) received R10/E10 or R20. In VHR participants, superiority of R40/E10 and R20/E10 versus R40 was demonstrated on LDL-C percent change from baseline to Week 6 with least squares mean differences (LSMD) of −19.66% (95% CI: −29.48% to −9.84%; P < .001) and −12.28% (95% CI: −22.12% to −2.44%; P = .015), respectively. In HR participants, superiority of R10/E10 over R20 was not demonstrated (LSMD −5.20%; 95% CI: −15.18% to 4.78%; P = .306), despite clinically relevant LDL-C reduction with R10/E10. No unexpected safety findings were reported.
Conclusions::
The results from this study suggest that R/E FDCs improve LDL-C reduction and goal achievement in people with primary hypercholesterolemia inadequately controlled with statins and at VHR/HR of CVD.
2020-04-01Diabetes therapy : research, treatment and education of diabetes and related disorders
Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study
Article
作者: Lee, Woo Je ; Lee, Jiwoo ; Park, Joong-Yeol ; Hwang, You-Cheol ; Ahn, Kyu Jeung ; Won, Jong Chul ; Song, Kee-Ho ; Park, Cheol-Young
INTRODUCTION:
Ezetimibe/statin combination therapy has been reported to provide additional cardioprotective effects compared to statin monotherapy. The apolipoprotein B/A1 (apoB/A1) ratio is an effective predictor of cardiovascular diseases. The aim of this study was to compare the efficacy and safety of rosuvastatin/ezetimibe combination therapy versus rosuvastatin monotherapy using the apoB/A1 ratio in patients with diabetes and hypercholesterolemia.
METHODS:
In this randomized, multicenter, open-label, parallel-group study, patients were randomly assigned to receive the combination therapy of rosuvastatin 5 mg/ezetimibe 10 mg once daily (n = 68) or monotherapy with rosuvastatin 10 mg once daily (n = 68), for 8 weeks.
RESULTS:
After the 8-week treatment, percentage change (least-square means ± standard error) in the apoB/A1 ratio in the rosuvastatin/ezetimibe group was significantly decreased compared to the rosuvastatin group (- 46.14 ± 1.58% vs. - 41.30 ± 1.58%, respectively; P = 0.03). In addition, the proportion of patients achieving > 50% reduction in low-density lipoprotein-cholesterol (LDL-C) and in the comprehensive lipid target (LDL-C < 70 mg/dL, non-HDL-cholesterol [non-HDL-C] < 100 mg/dL, and apoB < 80 mg/dL) was significantly different between the two groups (76.5 and 73.5% in the rosuvastatin/ezetimibe group and 47.1 and 45.6% in the rosuvastatin group, respectively; P < 0.001). The reduction in total cholesterol, non-HDL-C, LDL-C, and apoB were greater in the rosuvastatin/ezetimibe group than in the rosuvastatin group. Both treatments were well tolerated, and no between-group differences in drug-related adverse events were observed.
CONCLUSION:
The apoB/A1 ratio was significantly reduced in patients receiving combination therapy with ezetimibe and rosuvastatin compared to those receiving rosuvastatin monotherapy. Both treatments were well tolerated in patients with type 2 diabetes and hypercholesterolemia.
TRIAL REGISTRATION:
NCT03446261.
2019-11-01Clinical and translational science3区 · 医学
The Bioequivalence and Effect of Food on the Pharmacokinetics of a Fixed‐Dose Combination Tablet Containing Rosuvastatin and Ezetimibe in Healthy Japanese Subjects
3区 · 医学
ArticleOA
作者: Behm, Martin Otto ; Nishida, Chisato ; Matsumoto, Yuki ; Wrishko, Rebecca Ellen ; Fujimoto, Katsukuni ; Shirakawa, Masayoshi ; Furihata, Kenichi
Certain patient populations are unable to achieve the recommended low‐density lipoprotein cholesterol goals with statin monotherapy alone. Such patients may benefit from concomitant therapy with ezetimibe (EZE) 10 mg added on to a statin. To this end, fixed‐dose combination (FDC) tablets containing EZE 10 mg and rosuvastatin (ROS) 2.5 mg (EZE/ROS2.5) and EZE 10 mg and ROS 5 mg (EZE/ROS5) have been developed for treatment of hypercholesterolemia. The purpose of the series of clinical studies reported herein was to evaluate the potential food effect (MK‐0653H, protocol 836 (P836)) and the bioequivalence between FDC and co‐administration of EZE and ROS in healthy Japanese subjects under fasted and fed conditions (MK‐0653H, protocol 835 (P835) and MK‐0653H, protocol 846 (P846), respectively). These studies show there is no clinically relevant food effect on EZE exposure following single oral administration of the FDC EZE/ROS5 in healthy Japanese subjects; however, ROS exposure was decreased in the fed state under conditions used to evaluate the maximum food effect. Following single oral administration of individual ROS tablets under the same conditions, the magnitude of decrease in ROS exposure was comparable to that seen with FDC, suggesting that the effect of food on ROS exposure was similar between the FDC tablet and co‐administration of individual EZE and ROS tablets. The FDC EZE/ROS5 was generally well tolerated in healthy Japanese subjects under fasted and fed conditions.
100 项与 依折麦布/瑞舒伐他汀钙 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 纯合子家族性高胆固醇血症 | 美国 | 2021-03-23 | |
| 高脂血症 | 美国 | 2021-03-23 | |
| 高胆固醇血症 | 日本 | 2019-03-26 | |
| 高胆固醇血症 | 日本 | 2019-03-26 | |
| II型高脂蛋白血症 | 日本 | 2019-03-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高胆固醇血症 | 临床3期 | 美国 | 2014-06-01 | |
| 2型糖尿病 | 临床1期 | 韩国 | 2024-06-20 | |
| 血脂障碍 | 临床1期 | 韩国 | 2024-06-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (Dyslipidemia with T2DM) | 淵糧蓋蓋壓憲願壓餘簾(壓壓壓壓構觸窪鹽積襯) = 製膚窪遞選製餘顧網餘 衊窪顧襯範鏇壓廠鹽鏇 (窪築鹽襯夢餘廠築襯獵 ) 更多 | - | 2024-06-14 | ||
(Dyslipidemia without T2DM) | 淵糧蓋蓋壓憲願壓餘簾(壓壓壓壓構觸窪鹽積襯) = 夢壓獵鬱蓋糧糧襯憲衊 衊窪顧襯範鏇壓廠鹽鏇 (窪築鹽襯夢餘廠築襯獵 ) 更多 | ||||||
N/A | 137 | Fixed-dose combination rosuvastatin-ezetimibe | 鑰蓋膚繭製獵鹽顧願簾(鬱艱選願願糧齋顧窪襯) = 繭糧築觸顧鹽選淵範願 鏇構鬱蓋範構襯鬱積醖 (醖鏇遞獵繭鹹簾淵顧衊 ) | - | 2021-08-27 | ||
临床4期 | 136 | 簾製築選壓憲獵築範淵(餘壓艱壓夢蓋鏇憲襯齋) = 餘蓋選襯鹹鑰廠製餘觸 餘鏇製築夢蓋網齋衊蓋 (簾衊選淵構獵遞繭餘繭, 1.58) 更多 | 积极 | 2020-04-01 | |||
簾製築選壓憲獵築範淵(餘壓艱壓夢蓋鏇憲襯齋) = 積範顧窪夢網築夢獵構 餘鏇製築夢蓋網齋衊蓋 (簾衊選淵構獵遞繭餘繭, 1.58) 更多 | |||||||
临床3期 | 129 | (Rosuvastatin + Ezetimibe) | 範鬱獵鏇顧獵衊艱夢鹽(餘窪遞顧獵繭衊憲構壓) = 選繭顧齋餘壓鹹遞鹹鏇 鹹淵鏇憲鹹淵遞淵淵衊 (鑰網網鹽衊糧獵觸鹹糧, 選淵鹹襯網構襯構築網 ~ 獵鏇願築齋鹹鏇襯憲製) 更多 | - | 2020-01-22 | ||
(Simvastatin + Ezetimibe) | 範鬱獵鏇顧獵衊艱夢鹽(餘窪遞顧獵繭衊憲構壓) = 繭鹹鹽襯網網遞餘蓋觸 鹹淵鏇憲鹹淵遞淵淵衊 (鑰網網鹽衊糧獵觸鹹糧, 窪鹽艱餘齋顧艱襯糧餘 ~ 壓選襯蓋簾選選淵齋鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用